**Moncrieffe et al 2010 Supplementary Material**

**Table S1: Drug dose, route, toxicity and co-administration of steroids in responders (ACR70 cases) and non-responders (UK cohort)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Responders (ACR-Ped70)** | **Non responders (NR)** | **p value** |
| Mean (SD) dose MTX per week | 12.19 (2.59) | 12.62 (3.4) | NS |
| MTX route, oral: subcutaneous (%) | 70.2:29.8 | 69.8:30.1 | NS |
| Patients who had joint injections in 3 months prior to MTX or during MTX therapy (%) | 42.86 | 41.07 | NS |
| Patients given steroids duringMTX treatment (%) | 47.62 | 44.64 | NS |
| Patients who suffered GI toxicity (nausea and vomiting just pre-, or post-MTX administration)\* | 32.4 | 30.7 | NS |

SD – 1 standard deviation; \* toxicity data available on 72% of cases; GI- gastrointestinal